Today (October 30th), Huiyu Private Equity Fund Management (Huzhou) Co., Ltd. (referred to as “Huiyu Investment”) announced the official signing of a contract with Bloomage Biotech and Huzhou Industrial Group. They have jointly established an industry investment fund focused on life sciences and the broader health sector, with a total scale of 1 billion yuan ($136.7 million). Huiyu Investment will serve as the fund manager.
It is reported that the fund will primarily focus on innovative projects in the field of life sciences, including but not limited to biotechnology, medical devices, genetic engineering, and the broader wellness sector. It will leverage Bloomage Biotech’s leading industrial advantages in the field of life sciences and combine them with Huiyu Investment’s professional investment capabilities to provide strategic consulting and operational support to high-quality innovative enterprises. The aim is to assist these enterprises in achieving technology transfer and commercialization.
Huiyu Investment stated that this collaboration with Bloomage Biotech aims to leverage their capabilities in biotechnology, research and development, manufacturing, product application, and commercial sales. It will provide more businesses with support, strategic consulting, high-tech technology transfer, and rapid growth at the commercialization level.
Public information shows that Huiyu Investment was established in 2017 and has invested in over 40 external projects, including Bloomage Biotech, Xuzhou B&C Chemical Co. Ltd., Zhizhen Optics, Perfect Optics, and MDHC.
